Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Taxane-containing chemotherapy regimens

References

1 National Breast Cancer Centre. Clinical practice guidelines for the management of early breast cancer (2nd Edition). Canberra: Commonwealth of Australia 2001.

2 Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007, Issue 4.

3 National Breast and Ovarian Cancer Centre. Taxanes for neoadjuvant treatment of early breast cancer: a systematic review. National Breast and Ovarian Cancer Centre, Surry Hills, NSW, 2008.

4 Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976–83.

5 Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381–87.

6 Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–13.

7 Goldstein L. O’Neill A, Sparano J, et al. E2197: phase IIIAT vs AC in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings 2005;Abstract 512.

8 Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluoroucil. J Clin Oncol ASCO Annual Meeting Proceedings 2005;Abstract 513.

9 Martin M, Rodriguez-Lescure A, Ruiz A, et al. Multicentre, randomized phase IIIstudy of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC (90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. San Antonio Breast Cancer Symposium 2005;Abstract 39.

10 Fountzilas G, Skarlos D, Dafni U, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast III Oncol 2005;16:1762–71.

11 Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686–96.

12 Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.

13 Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664–71.

14 Bianco AR, De Matteis A, Manzione L, et al. Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: results of the taxit 216 multicenter phase III trial. J Clin Oncol ASCO Annual Meeting Proceedings 2006;24:LBA520.

15 Crown JP, Francis P, Di Leo A. Docetaxel given concurrently with or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer, in comparison with non-taxane combination chemotherapy. First results of the BIG 2-98 trial at 5 years median follow-up. J Clin Oncol ASCO Annual Meeting Proceedings Part 1 2006;24(18S):LBA519.

16 Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.

17 Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17(11):3412–7.

18 Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22(24):4958–65.

19 Learn PA, Yeh IT, McNutt M, et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer. 2005;103(11):2252–60.

20 Malamos N, Kosmas C, Antonopoulos MJ, et al. Prospective randomized study of neoadjuvant chemotherapy (NACT) with paclitaxel/epirubicin (PE) versus fluorouracil/epirubicin/cyclophosphamide (FEC) in operable stage II–IIIA breast cancer (BC). Ann Oncol. 1998;9(4).

21 Lee HG, Lee JJ, Jung KH, et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis. J Clin Oncol ASCO Meeting 2004;22(14S suppl 15):607.

22 Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol. 2005;23(13):2988–95.

23 Hutcheon AW, Heys SD and Sarkar TK. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat. 2003;82(suppl 1):s6.

24 National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra, Commonwealth of Australia, 2000.

25 National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Canberra: Commonwealth of Australia, 2003.

26 Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496–506.***

27 Brain EGC, Bachelot T, Serin D et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+/=3) breast cancer (BC) patients (pts): First analysis of toxicity. J Clin Oncol ASCO Annual Meeting Proceedings 2004 22;14S;Abstract 617.

28 Martin M Lluch A, Segui MA, et al. Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer : An interim safety analysis of the GEICAM 9805 study. J Cl Oncol ASCO Annual Meeting Proceedings 2004 22;Abstract 620.

29 Participating Institutions of Goim 9902 Trial, Italian Cooperative Group, Rome, Italy. Epirubicin and Cyclophosphamide (EC) vs Docetaxel Followed by EC in Adjuvant Treatment of Node Positive Breast Cancer. A Multicenter Randomized Phase III Study. J Clin Oncol, 2001 ASCO Annual Meeting Proceedings. 20; Abstract 1836.

30 Participating Institutions to GONO-MIG 5 study. Absence of Clinically Relevant Cardiotoxicity in Early Breast Cancer Patients Treated with the Association of Epirubicin Plus Paclitaxel: Results from the Italian Mig 5 Study. J Clin Oncol ASCO Annual Meeting Proceedings 2000 19: Abstract 363.

31 National Cancer Institute Clinical Trials (PDQ®) NCI-H99-0038 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=67305&version=HealthProfessional&protocolsearchid=3554372 Accessed: 22 August 2007.

32 Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006; Abstract 53.

33 National Cancer Institute Clinical Trials (PDQ®) FRE-FNCLCC-PACS-04/0005 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=269909&version=HealthProfessional&protocolsearchid=3554380 Accessed: 22 August 2007.

34 National Cancer Institute Clinical Trials (PDQ®) ICR-TACT http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=69311&version=HealthProfessional&protocolsearchid=3554384 Accessed: 22 August 2007.

35 National Cancer Institute Clinical Trials (PDQ®) EORTC-10994 http://www.cancer.gov/clinicaltrials/EORTC-10994 Accessed: 22 August 2007.

36 National Cancer Institute Clinical Trials (PDQ®) INTENS: IKO 2005-01 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=483044&version=HealthProfessional&protocolsearchid=3554369 Accessed: 22 August 2007.

***This article was considered by the NBOCC’s Taxanes Subgroup but published after March 2007

Published using CeCC Docbook Manager